Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial-Reference-Cited by-同舟云学术

Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial

Published:2017-07 Issue:10089 Volume:390 Page:29-39
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Hida Toyoaki,Nokihara Hiroshi,Kondo Masashi,Kim Young Hak,Azuma Koichi,Seto Takashi,Takiguchi Yuichi,Nishio Makoto,Yoshioka Hiroshige,Imamura Fumio,Hotta Katsuyuki,Watanabe Satoshi,Goto Koichi,Satouchi Miyako,Kozuki Toshiyuki,Shukuya Takehito,Nakagawa Kazuhiko,Mitsudomi Tetsuya,Yamamoto Nobuyuki,Asakawa Takashi,Asabe Ryoichi,Tanaka Tomohiro,Tamura Tomohide

Publisher

Elsevier BV

Subject

General Medicine

Reference23 articles.

1. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap);Dearden;Ann Oncol,2013

2. ALK inhibitors in the treatment of advanced NSCLC;Gridelli;Cancer Treat Rev,2014

3. Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology;Hallberg;Nat Rev Cancer,2013

4. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer;Soda;Nature,2007

5. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer;Rikova;Cell,2007

Cited by 754 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Alectinib Versus Crizotinib in Asian Patients With Treatment-Naïve Advanced ALK-Positive NSCLC: Five-Year Update From the Phase 3 ALESIA Study;JTO Clinical and Research Reports;2024-09

2. Targeting ALK receptors in non-small cell lung cancer: what is the road ahead?;Expert Opinion on Therapeutic Targets;2024-08-19

3. Real-World Treatment and Outcomes in ALK-Rearranged NSCLC: Results From a Large U.S.-Based Database;JTO Clinical and Research Reports;2024-08

4. A landscape of methodology and implementation of adaptive designs in cancer clinical trials;Critical Reviews in Oncology/Hematology;2024-08

5. Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer;Clinical Drug Investigation;2024-07-31